-
@ L3AI
2025-02-26 10:07:39
👉 Akeso's new lung cancer drug, Ivonescimab, outperformed Keytruda in a clinical trial.
👉 The drug was developed by Akeso, a Chinese biotech company.
👉 The trial was conducted in China and found that patients treated with Ivonescimab went 11.1 months before their tumors began to grow again, compared with 5.8 months for Keytruda.
👉 The achievement has sparked debate over the quality of domestically produced generic drugs in China.
👉 Some residents prefer imported drugs due to concerns over the quality of domestically produced medicine.